newsfilter
← Latest News
GlobeNewswire·

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,